Eli Lilly (NY:LLY)

1,143.12 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

2 Cash-Producing Stocks for Long-Term Investors and 1 Facing Headwinds

Today 0:34 EDT

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...

Via StockStory

Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock ↗

October 05, 2026

The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error.

Via The Motley Fool

This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled ↗

October 05, 2026

Eli Lilly is partnering with Ginkgo Bioworks on drug discovery.

Via The Motley Fool

Topics Artificial Intelligence

Eli Lilly (NYSE:LLY) Combines Strong Growth With a High-Quality Technical Setup ↗

October 03, 2026

Via Chartmill

If I Were in My 40s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever ↗

October 05, 2026

Owning a low-cost index fund is one of the simplest ways to build wealth in the stock market over the long term.

Via The Motley Fool

Topics ETFs Economy Retirement

Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 05, 2026

Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend...

Via The Motley Fool

Topics Intellectual Property

Here Are My Top 4 Stocks to Buy in October ↗

October 05, 2026

Get 'em while they're still on sale. Catalysts are on the horizon.

Via The Motley Fool

Topics Artificial Intelligence

Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech ↗

October 05, 2026

Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility and recent outperformance.

Via The Motley Fool

Topics ETFs

Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB ↗

October 05, 2026

VHT offers broad sector exposure, while IBB concentrates on biotech with higher growth but steeper drawdowns.

Via The Motley Fool

Topics ETFs

1 Mid-Cap Stock to Keep an Eye On and 2 We Ignore

October 05, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...

Via StockStory

2 Growth Stocks with All-Star Potential and 1 We Brush Off

October 05, 2026

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...

Via StockStory

Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? ↗

October 04, 2026

Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.

Via The Motley Fool

Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet ↗

October 04, 2026

Can anyone stop Eli Lilly’s progress in the weight loss market?

Via The Motley Fool

Eli Lilly Just Announced Something Big. Here’s What It Means for Investors. ↗

October 04, 2026

The company is the leader in a key growth market.

Via The Motley Fool

Wall Street Is Bracing for the Fed's Next Move on Rates. These 3 Stocks Win Either Way. ↗

October 03, 2026

Rising interest rates are unlikely to change the dynamics in the healthcare sector, where people are willing to pay for care.

Via The Motley Fool

Topics Economy

3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note ↗

October 03, 2026

With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.

Via MarketBeat

Topics Bonds Retirement

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP ↗

October 02, 2026

VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.

Via The Motley Fool

Topics ETFs

Novo Nordisk Strikes Nearly $4 Billion in 2 Deals. Here's What That Means for Investors ↗

October 02, 2026

The company's search for its next wave of billion-dollar drugs continues.

Via The Motley Fool

3 of the Best ETFs to Buy and Hold if a Recession Is Coming ↗

October 02, 2026

VHT, BND, and VOO could be your best bets in the next economic downturn.

Via The Motley Fool

Topics ETFs Economy Regulatory Compliance

2026 Biotech Watchlist IBRX, PACB, IGC, VIVS Lead 7 Stocks in Focus

October 01, 2026

Via AB Newswire

Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? ↗

October 01, 2026

JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.

Via The Motley Fool

Could Eli Lilly's Newest Weight Loss Strategy Pay Off for Decades? ↗

October 01, 2026

The company is constantly thinking big.

Via The Motley Fool

Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy ↗

September 30, 2026

Could this be what Novo needs to turn things around?

Via The Motley Fool

Topics Initial Public Offering

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. ↗

September 30, 2026

There could be more catalysts for the biotech over the next 18 months.

Via The Motley Fool

2 Outstanding Dividend Stocks to Buy and Hold for a Decade ↗

September 30, 2026

There is probably no dividend cut on the horizon for these healthcare companies.

Via The Motley Fool

Topics Artificial Intelligence

3 Emerging Biotech Stocks With Significant Upside Potential ↗

September 30, 2026

Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.

Via MarketBeat

Topics Intellectual Property

Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug ↗

September 30, 2026

Eli Lilly already beat its next-generation weight-loss drug, retatrutide, and it hasn't even hit the market.

Via Investor's Business Daily

Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market. ↗

September 30, 2026

Phase three trials on Eli Lilly's new weight loss drug, TRIUMPH-2, showed strong results.

Via The Motley Fool

Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market? ↗

September 30, 2026

Roche is increasingly looking like a notable contender in this fast-growing area.

Via The Motley Fool

4 Stocks That Could Split Next—and Why Investors Are Watching ↗

September 30, 2026

AutoZone, Eli Lilly, Meta Platforms, and Costco all trade at high share prices, making them candidates for stock splits as analysts raise price targets and cite strong fundamentals.

Via MarketBeat

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.